# A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Study · id `cardio:ct-nct07379333` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07379333](<https://clinicaltrials.gov/study/NCT07379333>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07379333

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 118 participants.

## Technical summary

Registry record NCT07379333. Randomized; double masking; primary purpose treatment. Start 2026-04-13 (actual); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 118 participants (planned count; ClinicalTrials.gov record NCT07379333, source copy `cardio:ctgov-nct07379333-2026-05-13`, retrieved 2026-10-26)
- Started: 2026-04-13 (actual) (ClinicalTrials.gov record NCT07379333, source copy `cardio:ctgov-nct07379333-2026-05-13`, retrieved 2026-10-26)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07379333, source copy `cardio:ctgov-nct07379333-2026-05-13`, retrieved 2026-10-26)
- Completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT07379333, source copy `cardio:ctgov-nct07379333-2026-05-13`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07379333, source copy `cardio:ctgov-nct07379333-2026-05-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07379333-2026-05-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
- Condition: Type 2 Diabetes
- Intervention (Drug): HM11260C
- Intervention (Drug): Placebo
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: 9a90964b8a20fe0e0223a1ae3c72fe16bd59ed1df9b80084ca1fa0f8f9bb0cf4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
